JW Pharmaceutical Resumes Sales of SK Bioscience's Influenza Vaccine 'SkyCell Flu Quadrivalent'

JW Shinyak announced on the 21st that it will resume sales of SK Bioscience's influenza vaccine 'Skycellflu Quadrivalent.'

JW Pharmaceutical Gwacheon Office Building Exterior.
[Photo by JW Pharmaceutical]

Since 2016, JW Shinyak has signed a joint sales agreement with SK Bioscience for Skycellflu Quadrivalent and has been responsible for sales and marketing activities targeting specialized clinics such as dermatology, urology, and plastic surgery.

The influenza vaccine Skycellflu Quadrivalent is a cell culture-based influenza vaccine developed by SK Bioscience. A single dose provides protection against four types of influenza viruses: two types of influenza A virus and two types of influenza B virus.

SK Bioscience had suspended production of Skycellflu Quadrivalent for the past two years to supply the COVID-19 vaccine 'Skycovione.' However, anticipating a sharp increase in influenza incidence this year due to the lifting of social distancing measures and the removal of indoor mask mandates, SK Bioscience has resumed production of the influenza vaccine Skycellflu Quadrivalent.

With the normalization of Skycellflu Quadrivalent supply, JW Shinyak will resume the previously halted sales of the influenza vaccine. Furthermore, leveraging its own sales and marketing competitiveness, the company plans to expand its presence in the influenza vaccine market.

A JW Shinyak official stated, "Recently, the number of suspected influenza patients has exceeded 15 per 1,000 people, which is three times the epidemic threshold (4.9 per 1,000) according to the Korea Disease Control and Prevention Agency's statistics," adding, "We will strive to ensure there are no disruptions in vaccine supply around October, when influenza incidence is expected to surge."

This content was produced with the assistance of AI translation services.